Exposure Of Bisphenol Analogues In Chronic Kidney Disease and Dialysis Patients

Study on the Level of Bisphenol Compounds in Patients With Chronic Kidney Disease and Renal Replacement Therapy and Relationship Between Bisphenols and Dialyzer Membrane

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04100421

Enrollment

154

Registered

2019-09-24

Start date

2017-06-01

Completion date

2018-06-30

Last updated

2019-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, Hemodialysis Complication

Keywords

bisphenol, human exposure, chronic kidney disease, blood purification

Brief summary

In this retrospective study, the serum levels of Bisphenol A (BPA) and three BPA analogs, namely, bisphenol B (BPB), bisphenol S (BPS), and bisphenol F (BPF), in patients with CKD, patients on dialysis therapy and healthy control were investigated to find out if BPA and BPA analogs accumulates in patients with chronic kidney disease (CKD), and if hemodialysis filters contribute to bisphenol burden in patients on hemodialysis (HD).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* age 18; informed consent

Exclusion criteria

* absence of active inflammatory, infectious, malignant diseases, acute chronic kidney disease, or pregnancy at the initiation or during the study

Design outcomes

Primary

Measure	Time frame
Death	2017.01-2018.06

Countries

China

Outcome results